Gore Range Capital
Gore Range Capital is a venture firm focused on early-stage investments in skin health. Formed in 2015, the firm combines an operational private equity approach with early-stage venture guidance, providing strategic, financial and scientific expertise to companies that diagnose, prevent, treat, regenerate, or enhance skin health. The team leverages domain experience and networks in healthcare to partner closely with portfolio companies.
Industries
Nr. of Employees
small (1-50)
Portfolio
Described as an automated virtual care platform; Series B expanded to $20M (news).
#Virtual care / automated virtual healthcare
Raised $56.5M to build a connected AED network for cardiac arrest emergency response.
#Emergency medical devices / connected AED network
Announced first-in-man clinical results for ET-02 (hair loss) and closed a $40M Series A with a licensing deal.
#Therapeutics — hair loss
Closed a $17M financing round to fund development of an ovarian cancer diagnostic test.
#Diagnostics — liquid biopsy / ovarian cancer
Awarded up to $2.6M grant from the FDA Office of Orphan Products Development (press).
#Therapeutics / dermatology (rare disease indication)
Accelerating development of SGY-101 into clinical development for targeted fat reduction.
#Therapeutics — siRNA for focal fat reduction (aesthetic/medical dermatology)
Described as an automated virtual care platform; Series B expanded to $20M (news).
#Virtual care / automated virtual healthcare
Raised $56.5M to build a connected AED network for cardiac arrest emergency response.
#Emergency medical devices / connected AED network
Announced first-in-man clinical results for ET-02 (hair loss) and closed a $40M Series A with a licensing deal.
#Therapeutics — hair loss
Closed a $17M financing round to fund development of an ovarian cancer diagnostic test.
#Diagnostics — liquid biopsy / ovarian cancer
Awarded up to $2.6M grant from the FDA Office of Orphan Products Development (press).
#Therapeutics / dermatology (rare disease indication)
Accelerating development of SGY-101 into clinical development for targeted fat reduction.
#Therapeutics — siRNA for focal fat reduction (aesthetic/medical dermatology)